Author:
Murphy Melissa L.,Rogers Duncan
Abstract
Abstract
Purpose
To describe a complex case of ocular tuberculosis reactivation with anterior uveitis, choroiditis and inflammatory choroidal neovascular membrane (CNVM) following immune checkpoint inhibitor (ICPI) treatment of malignant mucosal melanoma.
Methods
A retrospective collection of medical history, clinical findings and multimodal imaging with literature review of the topic was conducted.
Results
A 52-year-old Romanian female developed reduced vision and photophobia after three cycles of ICPI therapy comprised of ipilimumab and nivolumab. Bilateral anterior uveitis, multiple left eye choroidal lesions and a CNVM were confirmed using slit-lamp examination with ancillary multimodal imaging. Retinal changes in the right eye as well as a history of previously treated posterior uveitis and high-risk ethnicity increased clinical suspicion for ocular tuberculosis (TB) reactivation. The diagnosis was confirmed by TB positivity on polymerase chain reaction (PCR) analysis of lung aspirate followed by significant clinical improvement on systemic anti-tubercular therapy (ATT), systemic steroids and anti-vascular endothelial growth factor (VEGF) therapy.
Conclusions
ICPIs can cause a myriad of ocular issues, both by primary immunomodulatory effects as well as secondary reactivation of latent disease.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Ophthalmology
Reference19 articles.
1. Li B, Chan HL, Chen P (2019) Immune checkpoint inhibitors: basics and challenges. Curr Med Chem 26(17):3009–3025
2. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD et al (2022) Long-term outcomes with Nivolumab Plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced Melanoma. J Clin Oncol 40(2):127–137
3. Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I (2020) Potential immune-related adverse events associated with monotherapy and combination therapy of Ipilimumab, Nivolumab, and Pembrolizumab for advanced Melanoma: a systematic review and meta-analysis. Front Oncol 10:91. https://doi.org/10.3389/fonc.2020.00091
4. Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM (2014) Ipilimumab-induced ocular and orbital inflammation-a case series and review of the literature. Ocul Immunol Inflamm 24(2):140–146
5. Golli AL, Nitu MF, Turcu F, Popescu M, Ciobanu-Mitrache L, Olteanu M (2019) Tuberculosis remains a public health problem in Romania. Int J Tuberc Lung Dis 23(2):226–231